Share on LinkedInShare on LinkedIn

ARTICLE · 26 FEBRUARY 2013

Court Affirms Utility Of Gleevec Patent

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

A commentary on a recent decision released by the Federal Court regarding utility and the promise of pharmaceutical patents.

CanadaIntellectual Property

"[Sound prediction's] introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents."
Snider J Gleevec

These words are part of a refreshing and practical approach that was adopted in a decision released February 19, 2013 by the Federal Court regarding utility and the promise of pharmaceutical patents.

By this decision, Justice Snider dismissed two impeachment actions brought by Teva and Apotex against Novartis relating to the compound patent for Novartis' breakthrough cancer drug Gleevec® (imatinib mesylate). In dismissing the actions, Justice Snider tempered the approach taken in some recent cases which imposed very high standards of proof and knowledge to establish a demonstration and sound prediction of utility, including the disclosure requirement. This decision is also important in that it is the first to comment on the effect of the recent Supreme Court of Canada (SCC) Viagra decision.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from